The Pharmacy Times® Pneumococcal Resource Center is a comprehensive resource for clinical news and expert insights for any infection caused by the bacteria Streptococcus pneumoniae, or pneumococcus.
October 21st 2024
Data presented at IDWeek also showed greater disease-prevention effects in the community with PCV21 compared with prior pneumococcal vaccines.
Influenza Prevention in the At-Risk Adult Population and the Pharmacist's Role in an Evolving Influenza Vaccin...
1.25 Credits / Immunization, Infectious Diseases
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Ac...
1.5 Credits / HIV/AIDS, Infectious Diseases
View More
Pneumococcal Disease Prevention for Older Adults and the Pharmacist’s Role in an Evolving Vaccine Landscape
1.0 Credit / Immunization, Infectious Diseases
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
FDA Approves Menveo Single-Vial Presentation for Disease Caused by Meningococcal Bacteria
October 17th 2022New presentation offers health care providers with a more convenient, ready-to-use immunization option for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W.
Read More
Study: Climate Hazards Aggravate More than Half of Human Diseases Caused by Pathogens
August 25th 2022Climatic hazards were implicated for enhancing specific aspects of pathogens, increasing capacity of pathogens to cause more severe illness, and diminishing human capacity to cope with pathogens, such as dengue, hepatitis, pneumonia, malaria, and zika.
Read More
FDA Approves Expanded Indication for Vaxneuvance Pneumococcal Vaccine
June 22nd 2022Vaxneuvance is now indicated for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.
Read More